These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2904990)

  • 1. Actions of buspirone in a putative model of anxiety in the mouse.
    Costall B; Kelly ME; Naylor RJ; Onaivi ES
    J Pharm Pharmacol; 1988 Jul; 40(7):494-500. PubMed ID: 2904990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroanatomical sites of action of 5-HT3 receptor agonist and antagonists for alteration of aversive behaviour in the mouse.
    Costall B; Kelly ME; Naylor RJ; Onaivi ES; Tyers MB
    Br J Pharmacol; 1989 Feb; 96(2):325-32. PubMed ID: 2522335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that central 5-hydroxytryptaminergic neurones are involved in the anxiolytic activity of buspirone.
    Carli M; Prontera C; Samanin R
    Br J Pharmacol; 1989 Apr; 96(4):829-36. PubMed ID: 2568143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buspirone decreases the activity of 5-hydroxytryptamine-containing dorsal raphe neurons in-vitro.
    Trulson ME; Arasteh K
    J Pharm Pharmacol; 1986 May; 38(5):380-2. PubMed ID: 2872315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT ipsapirone and buspirone in the rat.
    Schreiber R; De Vry J
    Eur J Pharmacol; 1993 Nov; 249(3):341-51. PubMed ID: 7904566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different effects of intracerebral and systemic administration of buspirone in the forced swimming test: involvement of a metabolite.
    Cervo L; Grignaschi G; Samanin R
    Life Sci; 1988; 43(25):2095-102. PubMed ID: 2905409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleus incertus contributes to an anxiogenic effect of buspirone in rats: Involvement of 5-HT1A receptors.
    Kumar JR; Rajkumar R; Lee LC; Dawe GS
    Neuropharmacology; 2016 Nov; 110(Pt A):1-14. PubMed ID: 27436722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of buspirone on single unit activity in locus coeruleus and dorsal raphe nucleus in behaving cats.
    Wilkinson LO; Abercrombie ED; Rasmussen K; Jacobs BL
    Eur J Pharmacol; 1987 Apr; 136(1):123-7. PubMed ID: 3595712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug.
    VanderMaelen CP; Matheson GK; Wilderman RC; Patterson LA
    Eur J Pharmacol; 1986 Sep; 129(1-2):123-30. PubMed ID: 2876903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buspirone-induced changes in the serotonergic and non-serotonergic cells in the dorsal raphe nucleus of rats.
    Jahanshahi A; Lim LW; Steinbusch HW; Visser-Vandewalle V; Temel Y
    Neurosci Lett; 2010 Apr; 473(2):136-40. PubMed ID: 20178829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buspirone decreases the activity of serotonin-containing neurons in the dorsal raphe in freely-moving cats.
    Trulson ME; Trulson TJ
    Neuropharmacology; 1986 Nov; 25(11):1263-6. PubMed ID: 2879255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropharmacological and physiological validation of a computer-controlled two-compartment black and white box for the assessment of anxiety.
    Onaivi ES; Martin BR
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):963-76. PubMed ID: 2573111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of buspirone's anxiolytic action.
    Tunnicliff G
    Pharmacol Toxicol; 1991 Sep; 69(3):149-56. PubMed ID: 1796057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The actions of nicotine and cocaine in a mouse model of anxiety.
    Costall B; Kelly ME; Naylor RJ; Onaivi ES
    Pharmacol Biochem Behav; 1989 May; 33(1):197-203. PubMed ID: 2780777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of buspirone on the behaviour of control and stressed mice.
    Pokk P; Zharkovsky A
    J Physiol Pharmacol; 1998 Mar; 49(1):175-85. PubMed ID: 9594420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of mice in a black and white test box: validation as a model of anxiety.
    Costall B; Jones BJ; Kelly ME; Naylor RJ; Tomkins DM
    Pharmacol Biochem Behav; 1989 Mar; 32(3):777-85. PubMed ID: 2740429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone.
    Harada K; Aota M; Inoue T; Matsuda R; Mihara T; Yamaji T; Ishibashi K; Matsuoka N
    Eur J Pharmacol; 2006 Dec; 553(1-3):171-84. PubMed ID: 17074317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophysiological evidence that spiperone is an antagonist of 5-HT1A receptors in the dorsal raphe nucleus.
    Lum JT; Piercey MF
    Eur J Pharmacol; 1988 Apr; 149(1-2):9-15. PubMed ID: 2969339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of routes of administration and time course effects of zacopride and buspirone in mice using an automated light/dark test.
    Young R; Johnson DN
    Pharmacol Biochem Behav; 1991 Dec; 40(4):733-7. PubMed ID: 1687761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
    Haleem DJ; Samad N; Haleem MA
    Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.